We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s National Institute for Health and Care Excellence is recommending reimbursement of Novartis’ drug combination Mekinist and Tafinlar for treating unresectable or metastatic melanoma in patients with BRAF V600 mutations. Read More
Members of the Senate Special Committee on Aging took Valeant Pharmaceuticals’ International officials to task over what they called the company’s practice of buying drugs with no generic competition and “jacking up” the prices. Read More
As expected, Pfizer will pay $784.6 million to settle Justice Department allegations that a subsidiary deliberately reported inflated prices to Medicaid for two drugs. Read More
Despite grave doubts, an Indian high court judge is allowing two drugmakers to market and produce contested biosimilars of Roche’s breast cancer therapy Herceptin. Read More